Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Pertuzumab biosimilar by Mabscale for Metastatic Breast Cancer: Likelihood of Approval
Pertuzumab biosimilar is under clinical development by Mabscale and currently in Phase I for Metastatic Breast Cancer. According to GlobalData,...
Pertuzumab biosimilar by Mabscale for Breast Cancer: Likelihood of Approval
Pertuzumab biosimilar is under clinical development by Mabscale and currently in Phase I for Breast Cancer. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of Organon & Co's Pertuzumab biosimilar?
Pertuzumab biosimilar is a monoclonal antibody commercialized by Organon & Co, with a leading Phase III program in Human Epidermal...
Pertuzumab biosimilar by Organon & Co for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval
Pertuzumab biosimilar is under clinical development by Organon & Co and currently in Phase III for Human Epidermal Growth Factor...